Vol 9, No 1 (2024)
Original article
Published online: 2024-02-02

open access

Page views 163
Article views/downloads 121
Get Citation

Connect on Social Media

Connect on Social Media

Influence on polymorphism of visfatin (rs 4730153) and nesfatin (rs 1330) genes on the development of the metabolic syndrome

Małgorzata Poręba1, Agata Macionga1, Anna Gogola1, Nikola Szweda-Gandor1, Władysław Grzeszczak (†)1
Medical Research Journal 2024;9(1):42-47.

Abstract

Introduction: Visfatin and nesfatin are active proteins that are involved in the regulation of physiological
functions such as glucose metabolism and inflammatory response. This study aimed to assess the influence
of visfatins and nystatins gene variants on the occurrence of the full metabolic syndrome or its components.

Material and methods: The research cohort comprised 285 diabetic patients, 132 men and 153 women.
Specific DNA segments were amplified and labelled, and the rs 4730153 gene of visfatin and the rs 1330
gene of nesfatin were analysed. Real-Time PCR was conducted using fluorescence-labelled probes.

Results: The AA genotype of visfatin (rs 4730153) shows a positive association with glucose concentration
or pharmacological treatment in patients with type 2 diabetes, compared to AG and GG genotypes. The
GG genotype of nesfatin (rs 1330) shows a positive association with incidents of metabolic syndrome,
compared to the AA genotype.

Conclusions: Visfatin polymorphism in rs 4730153 may be associated with inappropriate glucose concentration.
Nesfatin polymorphism in rs 1330 may be associated with metabolic syndrome. Further studies in
a larger group of patients are necessary to completely assess this association.

Article available in PDF format

View PDF Download PDF file

References

  1. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2): 12.
  2. Jasińska A, Pietruczuk M. Adipocytokiny — białka o wielokierunkowym działaniu. J Lab Diagn. 2010; 46(3): 331–338.
  3. Chang YH, Chang DM, Lin KC, et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev. 2011; 27(6): 515–527.
  4. Liu SW, Qiao SB, Yuan JS, et al. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009; 71(2): 202–207.
  5. Zhong M, Tan Hw, Gong Hp, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf). 2008; 69(6): 878–884.
  6. Zheng LY, Xu X, Wan RH, et al. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetol Metab Syndr. 2019; 11: 60.
  7. Esteghamati A, Alamdari A, Zandieh A, et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract. 2011; 91(2): 154–158.
  8. Kim J, Oh CM, Kim H. The interplay of adipokines and pancreatic beta cells in metabolic regulation and diabetes. Biomedicines. 2023; 11(9): 2589.
  9. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006; 443(7112): 709–712.
  10. Cao X, Liu XM, Zhou LH. Recent progress in research on the distribution and function of NUCB2/nesfatin-1 in peripheral tissues. Endocr J. 2013; 60(9): 1021–1027.
  11. Nakata M, Manaka K, Yamamoto S, et al. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca(2+) influx through L-type channels in mouse islet β-cells. Endocr J. 2011; 58(4): 305–313.
  12. Larrad MM, Anchuelo AC, Pérez CF, et al. Obesity and cardiovascular risk: variations in visfatin gene can modify the obesity associated cardiovascular risk. Results from the segovia population based-study. Spain. PLoS One. 2016; 11(5): e0153976.
  13. Javanmard SH, Dehghananzadeh R, Rafiee L, et al. Genetic associations of the visfatin G-948T polymorphism with obesity-related metabolic traits in an Iranian population. J Res Med Sci. 2016; 21: 105.
  14. Marjani S, Nezhadali M, Hekmat A, et al. Investigating polymorphism with insulin resistance and non-alcoholic fatty liver diseases in iranian population. Iran J Public Health. 2022; 51(5): 1143–1151.
  15. Lai A, Chen W, Helm K. Effects of visfatin gene polymorphism RS4730153 on exercise-induced weight loss of obese children and adolescents of Han Chinese. Int J Biol Sci. 2013; 9(1): 16–21.
  16. Yu PL, Wang C, Li W, et al. Visfatin level and the risk of hypertension and cerebrovascular accident: a systematic review and meta-analysis. Horm Metab Res. 2019; 51(4): 220–229.
  17. Masood S, Khan T, Baloch A, et al. Association of Visfatin gene polymorphism with obesity related metabolic disorders among Pakistani population; a case control study. 2003.
  18. Soltanzadeh F, Nezhadali M, Pishkar L. The effect of Visfatin rs61330082 gene polymorphism on serum level of visfatin, type 2 diabetes and insulin resistance in an iranian population. Iranian Journal of Diabetes and Lipid Disorder. 2023; 23(3): 151–159.
  19. Ferrari G, Rodrigues J, Fernandes I, et al. Association between rs4730153 gene SNP and fasting glucose, triglyceride, HDL and body mass index levels iin overweight Brazilian adults. International Journal of Cardiovascular Sciences. 2016; 29(6): 471–476.
  20. Zegers D, Beckers S, Mertens IL, et al. Association between polymorphisms of the nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab. 2011; 103(3): 282–286.
  21. Li XS, Yan CY, Fan YJ, et al. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Ann Transl Med. 2020; 8(6): 290.
  22. Wang C, Wang Y, Hu W. Association of the polymorphism in NUCB2 gene and the risk of type 2 diabetes. Diabetol Metab Syndr. 2017; 9: 39.
  23. Chen YY, Chan RM, Tan KM, et al. The association of a nucleobindin 2 gene (NUCB2) variant with childhood adiposity. Gene. 2013; 516(1): 48–52.